The team will test a highly penetrant epidermal growth factor receptor inhibitor developed at UCLA and specifically designed for glioblastoma, a deadly and fast-growing brain tumor. EGFR is a protein frequently mutated in about 60% of people diagnosed with glioblastoma, making it an important target for treatment. This project opens a new paradigm for brain tumor drug development using a combination of drugs designed for brain tumors and companion imaging biomarkers for predicting or monitoring treatment response to these drugs.
Click here to continue reading the UCLA press release.
CTSI congratulates Dr. Ellingson on his NCI award. As a valued member of CTSI, Dr. Ellingson has received a wide range of support, including biostatistical services and Clinical and Translational Research Center support.